Latest Research And Development News

Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.

Neurotech International has locked in a $3.15 million secured loan against its anticipated R&D tax incentives to fund pivotal Phase III autism trials and ongoing operations.

Phoslock Environmental Technologies increased production significantly in the June quarter but faced a higher operating cash flow deficit and ongoing legal disputes.

Elixir Energy’s Lorelle-3H appraisal well in Queensland’s Taroom Trough has completed its initial clean-up phase, delivering promising dual phase flow rates and preparing for a critical tubing run to stabilise production before resuming testing.

Impact Minerals (ASX:IPT) has received a $310,000 Research and Development tax rebate for FY2025, supporting its Lake Hope High Purity Alumina project and investment in Alluminous Pty Ltd.

Orthocell Ltd delivered a standout FY26 with 44% revenue growth to A$13.2 million, powered by accelerating US sales of its nerve repair product Remplir and a robust cash position supporting further expansion.

State Gas Limited clears a year-long ATO review to access $4.1 million in R&D tax concessions, enabling debt repayment and bolstering cash reserves. Meanwhile, independent certification of 30.2 petajoules of 2P gas reserves at Rolleston West strengthens its development prospects.

Cleo Diagnostics (ASX:COV) has entered the analytical validation phase for its ovarian cancer test, progressing toward an FDA 510(k) submission expected in early 2027.

Bridge SaaS Limited has exited its non-core investment in Brightside Disability Support, recouping its initial outlay and sharpening its focus on AI-driven disability services and robotics innovation.

INOVIQ Limited hit a roadblock in expanding clinical validation of its EXO-OC™ ovarian cancer test due to unsuitable biobank samples, yet improved its diagnostic algorithm and progressed its CAR-exosome therapeutic program, maintaining a solid cash position of A$9.35 million.

Patrys has assigned its deoxymab intellectual property to Yale University in a deal granting it half of all future commercialisation revenue, reducing capital needs while keeping long-term upside.

Love Group Global Ltd (ASX:LVE) reported a record net operating cash flow of $974k for FY26, a 49% increase despite a 13% decline in customer cash receipts. The company plans to grow its matchmaking business in Asia and test expansion into the US and UK.